483 Samsung Biologics Nov 2019

483 Samsung Biologics Nov 2019

Matthew Casale FDA$119.00 - Available Now

FDA investigators audited the Samsung Biologics - Incheon, Korea (the Republic of) facility and issued inspectional observations (via FDA 483) on 01 Nov 2019.

Product details

  • Category: Human Drugs
  • Inspection end: 01 Nov 2019
  • Location: Incheon, Korea (the Republic of)
  • FEI: 3010479596
Add To Cart